Danaher Reports First Quarter 2025 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Danaher (DHR) PT Lowered to $260 at JPMorgan
April 22, 2025 1:45 PM EDTJPMorgan analyst Tycho W. Peterson lowered the price target on Danaher (NYSE: DHR) to $260.00 (from $280.00) while maintaining a Overweight rating.
The analyst comments "Like we noted in our first take earlier this morning, 1Q25 results (PR/Presentation/non-GAAP recs/Earnings supplement/10-Q) came in above expectations with notable performance in bioprocessing, while 2025 topline guidance was reiterated and bottom line guidance initiated bracketing the Street. 1Q non-GAAP core revenue growth was flat (vs. Street of -2.3% and guide of -LSD) as bioprocessing revenue grew +HSD in 1Q (consumables +LDD) with... More
